rs4646903 — CYP1A1 *2A (MspI, T3801C)

CYP1A1 *2A — The Oral Tissue Induction Amplifier

Cytochrome P450 1A1 (CYP1A1) is the cell's primary weapon against polycyclic aromatic hydrocarbons (PAHs)¹¹ polycyclic aromatic hydrocarbons (PAHs)
Flat, multi-ringed carbon compounds formed by incomplete combustion — found in cigarette smoke, grilled meat, chewing tobacco, and betel quid — but also the enzyme that converts those compounds into reactive, DNA-damaging epoxides. Whether CYP1A1 is protective or dangerous depends on whether Phase II enzymes (like glutathione S-transferases) are present to quickly neutralize what CYP1A1 generates. The rs4646903 variant (*2A, MspI) sits in the 3'-flanking non-coding region of the gene and modulates how much CYP1A1 protein gets made when carcinogens arrive — making it especially relevant for oral tissues directly exposed to tobacco and dietary PAHs.

The Mechanism

Unlike rs1048943 (Ile462Val), which increases the catalytic speed of individual CYP1A1 enzyme molecules, rs4646903 acts at the level of gene inducibility²² inducibility
How strongly the gene responds when its transcription is switched on by the aryl hydrocarbon receptor (AHR) upon carcinogen exposure. The T-to-C transition (T3801C in traditional numbering, reported as A→G on the genomic plus strand) in the 3'-flanking region is thought to increase mRNA stability or alter post-transcriptional regulation, resulting in higher CYP1A1 protein levels following AHR activation by PAHs or dioxins. In practical terms, when oral epithelial cells encounter tobacco smoke constituents or dietary charred compounds, carriers of the C (G on plus strand) allele produce more CYP1A1 enzyme — and therefore more reactive PAH epoxides — than carriers of the reference T (A) allele.

This variant often occurs on the same chromosome as the rs1048943 Ile462Val variant, forming the so-called *2B haplotype³³ *2B haplotype
The combination of *2A (MspI, rs4646903) + *2C (Ile462Val, rs1048943) on the same chromosomal copy — both more enzyme quantity and higher enzyme activity, particularly common in East Asian and Latino populations. When both variants co-occur, the effect is additive: more enzyme produced, and each molecule is more catalytically active.

The *2A variant has no effect on protein structure (it is non-coding), so its clinical relevance is entirely exposure-dependent. Without a PAH trigger — no tobacco, minimal charred food — there is little CYP1A1 to be induced, and the variant's effect is minimal.

The Evidence

Oral and oropharyngeal cancer. A HuGE-GSEC meta-analysis and pooled analysis⁴⁴ HuGE-GSEC meta-analysis and pooled analysis
Varela-Lema L et al. Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genetics in Medicine, 2008 combining 30 publications (7,783 subjects) found that the MspI homozygous variant genotype (CC/m2m2) was associated with significantly increased oral and oropharyngeal cancer risk: meta-analytic OR 1.9 (95% CI 1.4–2.7), pooled adjusted OR 2.0 (95% CI 1.3–3.1). Notably, the association was significant even among never-smokers (adjusted OR 1.8, 95% CI 1.1–2.9), pointing to dietary PAH exposure as a contributing factor independent of tobacco.

A dedicated meta-analysis of oral squamous cell carcinoma⁵⁵ meta-analysis of oral squamous cell carcinoma
Xie S et al. CYP1A1 MspI polymorphism and the risk of oral squamous cell carcinoma: Evidence from a meta-analysis. Molecular and Clinical Oncology, 2016 analysed 10 studies (1,505 cases, 1,967 controls) and found CC vs TT: OR 2.52 (95% CI 1.60–3.96). The association was driven by Asian populations; results in Caucasian and mixed-race groups were not significant.

A separate Asian-focused meta-analysis⁶⁶ separate Asian-focused meta-analysis
Xu JL et al. Association of CYP1A1 MspI polymorphism with oral cancer risk in Asian populations. J Cell Mol Med, 2016 with 12 studies (1,925 cases, 2,335 controls) confirmed the risk concentrated in homozygous carriers (m2/m2): all three genetic models were statistically significant.

Head and neck cancer overall. A 2022 Scientific Reports meta-analysis⁷⁷ 2022 Scientific Reports meta-analysis
Mohammadi H et al. Association between the CYP1A1 MspI polymorphism and risk of head and neck cancer: a meta-analysis. Scientific Reports, 2022 found consistent elevation across five genetic models: allelic OR 1.28 (95% CI 1.09–1.51), homozygous OR 1.68 (95% CI 1.16–2.45), dominant OR 1.66 (95% CI 1.27–2.16).

Laryngeal cancer. A meta-analysis of Asian populations⁸⁸ meta-analysis of Asian populations
Zeng W et al. CYP1A1 rs1048943 and rs4646903 polymorphisms associated with laryngeal cancer susceptibility among Asian populations. J Cell Mol Med, 2016 (10 studies, 748 cases, 1,558 controls) found GG vs AA: OR 1.53 (95% CI 1.31–2.21); G allele carriers vs AA: OR 1.33 (95% CI 1.04–1.71).

Gene-environment synergy with GSTM1. The interaction is most pronounced when the *2A variant is combined with GSTM1 null (absent Phase II detoxification). A Northeast Indian head and neck cancer study⁹⁹ Northeast Indian head and neck cancer study
Choudhury JH et al. Tobacco carcinogen-metabolizing genes CYP1A1, GSTM1, and GSTT1 polymorphisms and their interaction with tobacco exposure influence the risk of head and neck cancer. Tumour Biol, 2015 found that carriers of CYP1A1 TC/CC + GSTM1 null genotypes had a 3.52-fold increased risk overall (P<0.001), rising to 6.42-fold in smokers. This Phase I/Phase II imbalance — more reactive intermediates generated, fewer cleared — is the central biological mechanism.

Practical Actions

The *2A variant's clinical significance is almost entirely dependent on PAH exposure. Carriers who avoid tobacco and minimize dietary PAH exposure from charred foods substantially reduce their effective risk. For those who cannot or will not eliminate these exposures entirely, supporting Phase II detoxification capacity (cruciferous vegetables, sulforaphane) may partially compensate for the imbalance. Oral cancer screening awareness is warranted for homozygous carriers with significant tobacco or betel nut exposure history.

Interactions

CYP1A1 rs1048943 (Ile462Val/*2C): These two variants frequently co-occur on the *2B haplotype. When both are present, the combination produces more CYP1A1 enzyme (rs4646903 effect) and each molecule has higher catalytic activity (rs1048943 effect). This double hit amplifies PAH activation capacity more than either variant alone. Compound action proposed: CYP1A1 AG or GG (rs4646903) + CYP1A1 CT or CC (rs1048943) — combined recommendation: maximize PAH avoidance and cruciferous vegetable intake; consider discussing oral cancer screening with a dentist or physician if there is any tobacco or betel nut use history.

GSTM1 null (rs71748309, structural deletion): The gene-environment synergy between CYP1A1 *2A and GSTM1 null is the most clinically important interaction. Both AG and GG carriers of rs4646903 who also carry GSTM1 null show dramatically higher oral and head-and-neck cancer risk, particularly in tobacco users (OR 6.42 in smokers). Compound action proposed: rs4646903 AG/GG + GSTM1 null — avoidance of all tobacco and regular cruciferous vegetable intake as highest-priority combined recommendation.